CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
CG Oncology, Inc. will present first results from its CORE-008 Phase 2 trial assessing intravesical combination therapy for high-risk BCG-exposed and BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) at the American Urological Association (AUA) 2026 Annual Meeting. The company will also showcase research supported by its NMIBC research fe…